Results - Announcements
Lyka Labs Ltd share price declined by 0.22% to Rs 77.0 after the company's net profit tanked by 38.05% to Rs 1.27 crore, while revenue from operations slightly gained 4.47% to Rs 44.2 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, gaining 4.48%. It has improved by 6.57% over last one week and moved up slightly by 1.39% in last one month while the market capitalization of Lyka Labs Ltd has eased by 7.83% and 27.67% in the same period respectively.
Profit before tax (PBT) of Lyka Labs Ltd stood at Rs 1.07 crore in Q3 FY26, tumbling by 124.43% year-on-year, and nosediving by 45.13% quarter-on-quarter. EBITDA came in at Rs 3 crore, crashing by 179.89% YoY and plunging by 29.78% sequentially.
Total expenses grew marginally by 7.44% to Rs 42.73 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 13.58 crore, soaring by 21.25% YoY, while employee benefits expense was at Rs 12.58 crore, expanding by 9.49% YoY.
For the TTM ended FY26, revenue from operations declined slightly by 7.26% to Rs 128.44 crore, while net profit witnessed a sharp fall of 231.65% to Rs 10.44 crore, compared to previous TTM. EBITDA surged by 1640% to Rs 7.16 crore, and PBT tumbled by 205.94% to Rs 11.78 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 5.24 crore in FY26, as against Rs 1.9 crore in FY25.
Lyka Labs Ltd nosedived by 18.52% in last one year, underperforming the benchmark BSE Sensex which has declined by 11.78% during the same period.